BSE Pharma Sector Regulatory Filings — October 13, 2026

Q1 FY27 operating income rose ~10% YoY to Rs 15,300 Crore and India formulations grew 16%, but US formulations declined 10% and operating margin moderated to 29% from 31.1%; mixed operating picture

Organon acquisition (~$11.75B) to be funded with $2.0-2.5B cash/internal accruals plus $9.5-10.0B new debt, implying pro-forma combined revenue ~$12.4B and EBITDA margin of 28-30%; CRISIL AAA/Stable and ICRA AAA (Stable) affirmed on NCDs, supporting balance-sheet confidence

Rated AAA/Stable by CRISIL on a proposed Rs.15,000 Crore NCD programme despite expected leverage peak, indicating rating agencies view deleveraging path as credible

FYB206 (proposed Keytruda biosimilar) BLA accepted for USFDA review, believed to be the first publicly announced acceptance of a pembrolizumab biosimilar filing; USFDA decision potentially Q3 2027, with exclusive US/Canada rights under a December 2025 licence

Development achieved without a comparative Phase III efficacy trial, on a pathway agreed with USFDA in February 2025, lowering development cost and timeline risk for the asset

USFDA inspection of Moraiya (Ahmedabad) plant concluded 13 Oct 2026 with 5 observations, a negative regulatory data point that may delay approvals from that site

Milestone payment received from Zydus on BLA acceptance, with Formycon sharing gross profits of commercialization partners; amount undisclosed, limiting valuation read-through

Q2FY27 unaudited results and earnings call scheduled for 27 October 2026 (1600-1700 hrs IST); no figures disclosed yet, so the event is a catalyst without a directional signal

Board to consider Q2 and H1 FY27 (ended 30 Sep 2026) un-audited results on 3 November 2026; no figures in the filing, so no period comparison is available

KFin certified demat processing within the 15-day window for the quarter to 30 Sep 2026 (Reg 74(5)), a routine housekeeping confirmation with no financial content

Organon deal implies $9.5-10.0B of new debt plus assumption of Organon's ~$8.5B existing debt; net debt/EBITDA expected to reach 1.5-2.0x in FY2028 before deleveraging

US formulations sales fell 10% YoY amid generics weakness in Q1 FY27, the largest revenue drag in the period

Operating margin contracted to 29% from 31.1% (about 210 bps), indicating cost or mix pressure ahead of deal integration

Unresolved US FDA import alert on Halol (Dec 2022), warning letters at Dadra and Mohali, and OAI classification at Baska continue to constrain US supply and approvals

USFDA inspection at Moraiya plant closed with 5 observations; company has committed to remediate expeditiously, but outcome and any Form 483 follow-up timing are unknown

FYB206 USFDA decision is not expected until about Q3 2027, so revenue contribution from the Keytruda biosimilar is a multi-year, binary-risk story

Pro-forma EBITDA margin of 28-30% sits below the 29%+ run-rate implied for Sun alone, so the deal is margin-dilutive on a combined basis

Acquisition creates a ~$12.4B pro-forma revenue base with a larger US footprint; if integration delivers, the combined entity could re-rate on scale and diversification

India formulations grew 16% YoY, a durable domestic growth engine that offsets US generics weakness and supports earnings resilience

CRISIL AAA/Stable and ICRA AAA (Stable) on the NCD programme keep low-cost debt access open, reducing financing risk for the Organon funding plan

First publicly announced USFDA BLA acceptance for a pembrolizumab biosimilar; Keytruda is a very large oncology franchise, so a Q3 2027 approval would open a significant US and Canadian market opportunity

Development without a comparative Phase III efficacy trial lowers capital needs and time to market versus conventional biosimilar development

Formycon's global rights and gross-profit sharing in commercialization partnerships create a second route to participate in FYB206 upside (read-through for listed partners)

Unaudited results and call on 27 October 2026 are the next scheduled data point for the stock; investors can position ahead of the print with the call transcript as an input

Board meeting on 3 November 2026 provides the first H1 FY27 earnings print for the company, a near-term event for event-driven positioning

Zydus/Formycon FYB206 BLA acceptance signals Indian pharma moving up the value chain into complex biologics, with biosimilar approvals and licensing deals becoming a growth vector for Indian companies [implication: pipeline-led re-rating potential over 2027-2028]

Sun's US formulations fell 10% YoY while India formulations grew 16%, showing that domestic branded growth is currently outpacing US generics and reinforcing geographic diversification as a core theme [implication: favour companies with strong India franchises]

USFDA observations at Zydus (5 at Moraiya) and unresolved Sun site issues (Halol import alert, Dadra/Mohali warning letters, Baska OAI) show US facility compliance remains a sector-wide gating factor [implication: site-level FDA risk should be screened for every holding]

Sun's ~$11.75B Organon deal, with debt-funded structure and temporary leverage peak, shows Indian pharma moving toward larger, leverage-bearing deals to gain US scale, with rating agencies currently supportive [implication: watch for leverage and integration execution as the deal progresses]

Cipla (27 Oct) and GSK (3 Nov) results fall in the same window, meaning Q2 FY27 prints will be read together for margin and US generics trends across the sector [implication: use the cluster to test whether Sun's margin pressure is sector-wide]

Debt financing terms, integration milestones and any change to the 1.5-2.0x leverage path in FY2028; monitor for rating actions following the CRISIL and ICRA affirmations

Halol import alert, Dadra and Mohali warning letters and Baska OAI status; any re-inspection outcome is a major binary event

27 October 2026, 1600-1700 hrs IST; focus on US generics trends and margin commentary relative to Sun's Q1 print

Board meeting 3 November 2026; key read-across for India branded-generics growth and margin

Company response timeline and any Form 483 or follow-up inspection; relevant for site approvals and US supply

BLA review milestones and Health Canada decision; first major guidance point is USFDA decision around Q3 2027

Reg 74(5) confirmations are routine; watch the next quarterly results for any material change in demat or share-transfer activity